# DESTINY-PanTumor02 (NCT04482309)

> A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

No report yet. It can be ordered.

- Drugs tested: trastuzumab deruxtecan
- Indication: HER2-expressing solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04482309
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions: Trastuzumab deruxtecan
- Enrollment: 477
- Primary outcome: Objective Response Rate (ORR)

## Questions raised in the commentary

_Automated from the 40 newest of 222 indexed sources (Apr 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether HER2 testing variability changes treatment eligibility or expected benefit
- How HER2 expression level should guide treatment selection
- Whether the ovarian cancer evidence is sufficient to guide treatment decisions
- How interstitial lung disease risk should influence treatment and retreatment decisions

Also discussed: first-line development.

## Indexed commentary on DESTINY-PanTumor02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 81
- YouTube: 70
- Podcasts: 69
- Bluesky threads: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-pantumor02-nct04482309

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04482309", "email": "<work email>"}; the inbox owner confirms by the emailed link.